Integrated Solutions, Unified Teams: Enabling Collaboration Across the Continuum of Care

Structural heart (SH) disease has emerged as one of the fastest-growing subspecialties in cardiovascular care. Since the Centers for Medicare & Medicaid Services approved TAVR for low-risk patients in 2019, the population eligible to receive TAVR has more than doubled, and similar expansions are underway in mitral and tricuspid interventions. To help programs understand this transformation, this CV business white paper gathers real-world insights from leading academic SH programs. The paper identifies critical lessons and forward-thinking strategies to prepare SH programs for growth, particularly in the ambulatory surgery center space.

ACCESS CV BUSINESS WHITE PAPER